Skip to content
    Clinical Trials

    Aumolertinib Plus Radiotherapy Extends Progression-Free Survival in EGFR-Mutant NSCLC

    Bi et alSignal Transduction and Targeted Therapy

    Aumolertinib Plus Radiotherapy Extends Progression-Free Survival in EGFR-Mutant NSCLC
    The prospective, randomized phase III ADVANCE study evaluated a chemotherapy-free regimen combining 110 mg daily aumolertinib with definitive radiotherapy (RT) versus standard concurrent chemoradiotherapy (cCRT with cisplatin and pemetrexed) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring EGFR mutations (ChiCTR2000040590). While initial trial design planned for 98 participants to detect a hazard ratio (HR) of 0.5 for progression-free survival (PFS), the study was stopped early following a prespecified interim analysis after randomizing 43 eligible patients (24 experimental, 19 control) due to slow accrual, open-label loss of clinical equipoise, and a substantial observed PFS difference.
    At a median follow-up of 25.5 months, experimental therapy demonstrated marked superiority over cCRT, achieving a median PFS of 34.0 months compared with 7.4 months in the control arm (HR 0.15; P < 0.001). Median overall survival (OS) was not reached in the aumolertinib group versus 30.5 months in the control arm (HR 0.32; P = 0.09). From a tolerability perspective, adverse events including neutropenia and nausea occurred more frequently with chemoradiotherapy, and patient-reported quality of life favored the aumolertinib arm.
    These clinical trial findings were reinforced by a prespecified real-world validation cohort (n = 125; median follow-up 32.7 months; NCT04304638). In this cohort, EGFR tyrosine kinase inhibitors (TKIs) paired with RT showed efficacy comparable to TKIs combined with cCRT, with both TKI-containing strategies outperforming cCRT alone (P < 0.001). Together, the data support induction and concurrent aumolertinib plus definitive radiotherapy as an effective chemotherapy-free paradigm for unresectable stage III EGFR-mutated NSCLC.

    Key Takeaways

    • Aumolertinib combined with definitive radiotherapy significantly extended median progression-free survival compared with concurrent chemoradiotherapy (34.0 vs. 7.4 months; HR 0.15; P < 0.001) at a median follow-up of 25.5 months.
    • Median overall survival was not reached in the aumolertinib plus radiotherapy arm compared with 30.5 months in the chemoradiotherapy arm (HR 0.32; P = 0.09), with lower rates of neutropenia and nausea and superior quality of life in the experimental group.
    • In a prespecified real-world validation cohort of 125 patients, EGFR tyrosine kinase inhibitors plus radiotherapy demonstrated outcomes comparable to TKIs plus chemoradiotherapy, with both regimens demonstrating superiority over chemoradiotherapy alone (P < 0.001).
    Read the original sourceSignal Transduction and Targeted Therapy